Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has shown continued benefit over four years, according ...

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

Eli Lilly & Biogen's Alzheimer's drugs may offer minimal impact despite aggressive marketing. Click here to get insights on ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

Ready to get scared? Edmonton’s iconic Deadmonton Haunted House has revealed its 2025 themes — and they’ll send chills down ...

Arguably the FDA’s most anticipated decision this month is for a subcutaneous induction formulation of Biogen and Eisai’s ...

Buck up, baby boomers. Sixty may not be the new 40, but 80 could soon be the new 60. A trove of new Alzheimer’s research ...

NasdaqGS:BIIB 1 Year Share Price vs Fair Value Explore Biogen's Fair Values from the Community and select yours ...

Cannabinoids are specific chemical compounds found in cannabis, such as tetrahydrocannabinol (THC) and cannabidiol (CBD). Research is increasingly su ...